Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Webster Equity Partners
Acquired Company
Lifecore Biomedical
Description
Webster Equity Partners is acquiring Lifecore Biomedical, Inc. for $6.28 per share in cash. This acquisition also includes one non-tradable contingent value right per share. The transaction is part of a series of proposed mergers and acquisitions under investigation for potential shareholder rights violations.
Fundz sees it the moment Webster Equity Partners makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Frequently asked
Who acquired Lifecore Biomedical?
Lifecore Biomedical was acquired by Webster Equity Partners, based in New York. The deal was reported on September 29, 2026. Webster Equity Partners is a private equity firm focused on investing in and acquiring companies across various sectors. It seeks to enhance value by leveraging its industry expertise and management capabilities. Webster Equity Partners is privately held and operates in Financial Services.
When did Webster Equity Partners acquire Lifecore Biomedical?
Webster Equity Partners's acquisition of Lifecore Biomedical was reported on September 29, 2026. Webster Equity Partners is acquiring Lifecore Biomedical, Inc. for $6.28 per share in cash. This acquisition also includes one non-tradable contingent value right per share. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Lifecore Biomedical do?
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) focused on injectable fill/finish capabilities for the pharmaceutical industry. It is publicly traded (LFCR), operating in Manufacturing, and is based in Chaska.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.